EQONEX SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) W… – Press Release

[ad_1]

NEW YORK, May 20, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Eqonex Ltd. (“Eqonex” or the “Company”) EQOSQ and reminds investors of the June 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Eqonex stock or options between March 7, 2022 and November 29, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EQOS.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On March 7, 2022, Eqonex announced a “strategic partnership” with Bifinity, a payments technology company affiliated with Binance and launched that same day, which initially focused on leveraging “Digivault as an FCA regulated custodian, strengthening the technology supporting the Eqonex Exchange, and expanding Bifinity’s geographical footprint through Eqonex’s licensing framework.” In addition, the two companies announced that they “will continue to engage in non-binding discussions to explore potential merger opportunities, subject to regulatory approval[,]” and “explore opportunities to grow EQONEX’s digital asset investment solutions business.” Under the partnership, Bifinity issued Eqonex a $36 million convertible loan facility (the “Loan”) in exchange for a right to appoint from within Bifinity, Eqonex’s CEO, Chief Financial Officer and Chief Legal Officer, as well as two members for Eqonex’s board.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1)…

[ad_2]